rabacfosadine: has potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 16047979 |
| CHEMBL ID | 1823518 |
| SCHEMBL ID | 2734825 |
| MeSH ID | M0524829 |
| Synonym |
|---|
| gs-9219 |
| rabacfosadine |
| vdc-1101 |
| CHEMBL1823518 |
| 859209-74-8 |
| l-alanine, n,n'-(((2-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)ethoxy)methyl)phosphinylidene)bis-, diethyl ester |
| rabacfosadine [usan:inn] |
| gs 9219 |
| unii-m39bo43j9w |
| diethyl n,n'-(((2-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)ethoxy)methyl)phosphonoyl)-di-l-alaninate |
| vdc 1101 |
| m39bo43j9w , |
| rabacfosadine [usan] |
| l-alanine, n,n'-(((2-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)ethoxy)methyl)phosphinylidene)bis-, 1,1'-ethyl ester |
| rabacfosadine [green book] |
| rabacfosadine [mi] |
| rabacfosadine [inn] |
| SCHEMBL2734825 |
| DTXSID10235245 |
| D10723 |
| rabacfosadine (usan/inn) |
| CS-6590 |
| HY-13640 |
| DB12762 |
| Q27283428 |
| (2s,2's)-diethyl 2,2'-((((2-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)ethoxy)methyl)phosphoryl)bis(azanediyl))dipropanoate |
| ethyl (2s)-2-[[2-[2-amino-6-(cyclopropylamino)purin-9-yl]ethoxymethyl-[[(2s)-1-ethoxy-1-oxopropan-2-yl]amino]phosphoryl]amino]propanoate |
| rabacfosadina |
| rabacfosadinum |
| AKOS040742531 |
Rabacfosadine is a generally well tolerated, effective chemotherapy option for dogs with relapsed B-cell lymphoma.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rabacfosadine is a generally well tolerated, effective chemotherapy option for dogs with relapsed B-cell lymphoma." | ( Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Burgess, KE; Clifford, CA; Fan, TM; Morges, MA; Phillips, B; Saba, CF; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2018) | 2.64 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Response assessment and adverse event (AE) evaluation were performed every 21 days via VCOG criteria." | ( Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Burgess, KE; Clifford, CA; Fan, TM; Morges, MA; Phillips, B; Saba, CF; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2018) | 1.92 |
| " Response assessment and adverse event (Ae) evaluation were performed every 21 days via Veterinary Cooperative Oncology Group (VCOG) criteria." | ( Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Burgess, K; Clifford, C; Curran, K; Elmslie, R; Fan, T; Phillips, B; Post, G; Saba, CF; Thamm, D; Vail, D; Wright, Z, 2020) | 2 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Historical studies have suggested that every 21-day dosing is effective with acceptable toxicity." | ( Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Burgess, KE; Clifford, CA; Fan, TM; Morges, MA; Phillips, B; Saba, CF; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM, 2018) | 1.92 |
| " AEs were most commonly of gastrointestinal origin (hyporexia/diarrhoea) and generally resolved with supportive treatment and/or dosage adjustment." | ( Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials. Burgess, K; Clifford, C; Curran, K; Elmslie, R; Fan, T; Phillips, B; Post, G; Saba, CF; Thamm, D; Vail, D; Wright, Z, 2020) | 2 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID615067 | Antiproliferative activity against human CCRF-CEM after 72 hrs by XTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. |
| AID615223 | Immunomodulatory activity in C57BL/6 mouse peritoneal cells assessed as inhibition of LPS-induced NO production at 25 uM after 24 hrs by Griess reagent method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. |
| AID615065 | Antiproliferative activity against human HL60 after 72 hrs by XTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. |
| AID615064 | Antiproliferative activity against human HepG2 after 72 hrs by XTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. |
| AID615224 | Immunostimulatory activity in C57BL/6 mouse peritoneal cells assessed as stimulation of LPS-induced NO production at 25 uM after 24 hrs by Griess reagent method | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. |
| AID615066 | Antiproliferative activity against human HeLaS3 after 72 hrs by XTT assay | 2011 | European journal of medicinal chemistry, Sep, Volume: 46, Issue:9 | A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.79) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (26.67%) | 5.53% |
| Reviews | 2 (13.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||